Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Apo-Baclofen · DIN 02139332 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1994-12-31 · brand APO-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Apotex inc · schedule Prescription

DIN 02139332: Apo-Baclofen Raw flags: sec3=Y Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1595; ministry $0.1595 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02139332 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17246

Interchangeable products

Baclofen · DIN 02287021 · $0.1595 Baclofen · DIN 02544660 · $0.1595 Jamp Baclofen · DIN 02544482 · $0.1595 Lioresal · DIN 00455881 · $0.1595 Mylan-Baclofen · DIN 02088398 · $0.1595 PMS-Baclofen · DIN 02063735 · $0.1595 Ratio-Baclofen · DIN 02236507 · $0.1595

Shortage status: resolved shortage (ended 2024-08-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02139332

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Baclofen · DIN 02287021 Manufacturer: Sanis Health Inc.; listing date 2011-09-15 Health Canada: Marketed since 2010-02-25 · brand BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Sanis health inc · schedule Prescription

DIN 02287021: Baclofen Raw flags: sec3=Y Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1595; ministry $0.1595 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02287021 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77246

Interchangeable products

Apo-Baclofen · DIN 02139332 · $0.1595 Baclofen · DIN 02544660 · $0.1595 Jamp Baclofen · DIN 02544482 · $0.1595 Lioresal · DIN 00455881 · $0.1595 Mylan-Baclofen · DIN 02088398 · $0.1595 PMS-Baclofen · DIN 02063735 · $0.1595 Ratio-Baclofen · DIN 02236507 · $0.1595

Shortage status: resolved shortage (ended 2025-01-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02287021

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Baclofen · DIN 02544660 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-10-31 Health Canada: Marketed since 2024-05-31 · brand BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription

DIN 02544660: Baclofen Raw flags: sec3=Y Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id SIV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1595; ministry $0.1595 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544660 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103323

Interchangeable products

Apo-Baclofen · DIN 02139332 · $0.1595 Baclofen · DIN 02287021 · $0.1595 Jamp Baclofen · DIN 02544482 · $0.1595 Lioresal · DIN 00455881 · $0.1595 Mylan-Baclofen · DIN 02088398 · $0.1595 PMS-Baclofen · DIN 02063735 · $0.1595 Ratio-Baclofen · DIN 02236507 · $0.1595

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544660

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Jamp Baclofen · DIN 02544482 Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30 Health Canada: Marketed since 2025-09-12 · brand JAMP BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Jamp pharma corporation · schedule Prescription

DIN 02544482: Jamp Baclofen Raw flags: sec3=Y Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1595; ministry $0.1595 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544482 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103303

Interchangeable products

Apo-Baclofen · DIN 02139332 · $0.1595 Baclofen · DIN 02287021 · $0.1595 Baclofen · DIN 02544660 · $0.1595 Lioresal · DIN 00455881 · $0.1595 Mylan-Baclofen · DIN 02088398 · $0.1595 PMS-Baclofen · DIN 02063735 · $0.1595 Ratio-Baclofen · DIN 02236507 · $0.1595

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544482

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mylan-Baclofen · DIN 02088398 Manufacturer: Mylan Pharmaceuticals ULC; listing date 1996-10-01 Health Canada: Marketed since 2010-01-20 · brand MYLAN-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Mylan pharmaceuticals ulc · schedule Prescription

DIN 02088398: Mylan-Baclofen Raw flags: sec3=Y Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id MYL Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1595; ministry $0.1595 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02088398 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16534

Interchangeable products

Apo-Baclofen · DIN 02139332 · $0.1595 Baclofen · DIN 02287021 · $0.1595 Baclofen · DIN 02544660 · $0.1595 Jamp Baclofen · DIN 02544482 · $0.1595 Lioresal · DIN 00455881 · $0.1595 PMS-Baclofen · DIN 02063735 · $0.1595 Ratio-Baclofen · DIN 02236507 · $0.1595

Shortage status: resolved shortage (ended 2023-08-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02088398

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

PMS-Baclofen · DIN 02063735 Manufacturer: Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 1994-12-31 · brand PMS-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 10 MG · company Pharmascience inc · schedule Prescription

DIN 02063735: PMS-Baclofen Raw flags: sec3=Y Item: 122000003; group id 240; item number 0430; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1595; ministry $0.1595 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02063735 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15547

Interchangeable products

Apo-Baclofen · DIN 02139332 · $0.1595 Baclofen · DIN 02287021 · $0.1595 Baclofen · DIN 02544660 · $0.1595 Jamp Baclofen · DIN 02544482 · $0.1595 Lioresal · DIN 00455881 · $0.1595 Mylan-Baclofen · DIN 02088398 · $0.1595 Ratio-Baclofen · DIN 02236507 · $0.1595

Shortage status: resolved shortage (ended 2018-01-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02063735

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Apo-Baclofen · DIN 02139391 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1994-12-31 · brand APO-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Apotex inc · schedule Prescription

DIN 02139391: Apo-Baclofen Raw flags: sec3=Y Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3104; ministry $0.3104 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02139391 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17247

Interchangeable products

Baclofen · DIN 02287048 · $0.3104 Baclofen · DIN 02544679 · $0.3104 Jamp Baclofen · DIN 02544490 · $0.3104 Lioresal DS · DIN 00636576 · $0.3104 Mylan-Baclofen · DIN 02088401 · $0.3104 PMS-Baclofen · DIN 02063743 · $0.3104 Ratio-Baclofen · DIN 02236508 · $0.3104

Shortage status: resolved shortage (ended 2024-05-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02139391

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Baclofen · DIN 02287048 Manufacturer: Sanis Health Inc.; listing date 2011-09-15 Health Canada: Marketed since 2010-02-25 · brand BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Sanis health inc · schedule Prescription

DIN 02287048: Baclofen Raw flags: sec3=Y Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3104; ministry $0.3104 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02287048 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77247

Interchangeable products

Apo-Baclofen · DIN 02139391 · $0.3104 Baclofen · DIN 02544679 · $0.3104 Jamp Baclofen · DIN 02544490 · $0.3104 Lioresal DS · DIN 00636576 · $0.3104 Mylan-Baclofen · DIN 02088401 · $0.3104 PMS-Baclofen · DIN 02063743 · $0.3104 Ratio-Baclofen · DIN 02236508 · $0.3104

Shortage status: resolved shortage (ended 2023-09-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02287048

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Baclofen · DIN 02544679 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-10-31 Health Canada: Marketed since 2024-05-31 · brand BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription

DIN 02544679: Baclofen Raw flags: sec3=Y Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id SIV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3104; ministry $0.3104 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544679 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103324

Interchangeable products

Apo-Baclofen · DIN 02139391 · $0.3104 Baclofen · DIN 02287048 · $0.3104 Jamp Baclofen · DIN 02544490 · $0.3104 Lioresal DS · DIN 00636576 · $0.3104 Mylan-Baclofen · DIN 02088401 · $0.3104 PMS-Baclofen · DIN 02063743 · $0.3104 Ratio-Baclofen · DIN 02236508 · $0.3104

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544679

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Jamp Baclofen · DIN 02544490 Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30 Health Canada: Marketed since 2025-09-12 · brand JAMP BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Jamp pharma corporation · schedule Prescription

DIN 02544490: Jamp Baclofen Raw flags: sec3=Y Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3104; ministry $0.3104 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544490 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103304

Interchangeable products

Apo-Baclofen · DIN 02139391 · $0.3104 Baclofen · DIN 02287048 · $0.3104 Baclofen · DIN 02544679 · $0.3104 Lioresal DS · DIN 00636576 · $0.3104 Mylan-Baclofen · DIN 02088401 · $0.3104 PMS-Baclofen · DIN 02063743 · $0.3104 Ratio-Baclofen · DIN 02236508 · $0.3104

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544490

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mylan-Baclofen · DIN 02088401 Manufacturer: Mylan Pharmaceuticals ULC; listing date 1996-10-01 Health Canada: Marketed since 2010-03-24 · brand MYLAN-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Mylan pharmaceuticals ulc · schedule Prescription

DIN 02088401: Mylan-Baclofen Raw flags: sec3=Y Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id MYL Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3104; ministry $0.3104 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02088401 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16532

Interchangeable products

Apo-Baclofen · DIN 02139391 · $0.3104 Baclofen · DIN 02287048 · $0.3104 Baclofen · DIN 02544679 · $0.3104 Jamp Baclofen · DIN 02544490 · $0.3104 Lioresal DS · DIN 00636576 · $0.3104 PMS-Baclofen · DIN 02063743 · $0.3104 Ratio-Baclofen · DIN 02236508 · $0.3104

Shortage status: resolved shortage (ended 2023-10-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02088401

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

PMS-Baclofen · DIN 02063743 Manufacturer: Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 1994-12-31 · brand PMS-BACLOFEN · ATC M03BX01 BACLOFEN · form Tablet · route Oral · ingredients BACLOFEN 20 MG · company Pharmascience inc · schedule Prescription

DIN 02063743: PMS-Baclofen Raw flags: sec3=Y Item: 122000006; group id 240; item number 0431; lccId None; manufacturer id PMS Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3104; ministry $0.3104 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02063743 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15548

Interchangeable products

Apo-Baclofen · DIN 02139391 · $0.3104 Baclofen · DIN 02287048 · $0.3104 Baclofen · DIN 02544679 · $0.3104 Jamp Baclofen · DIN 02544490 · $0.3104 Lioresal DS · DIN 00636576 · $0.3104 Mylan-Baclofen · DIN 02088401 · $0.3104 Ratio-Baclofen · DIN 02236508 · $0.3104

Shortage status: resolved shortage (ended 2018-02-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02063743

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Baclofen Injection · DIN 02413620 Manufacturer: Sterimax Inc.; listing date 2015-08-26 Health Canada: Marketed since 2018-01-12 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 0.05 MG/1ML · company Sterimax inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02413620). DIN 02413620: Baclofen Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 122000024; group id 240; item number 0428; lccId None; manufacturer id STE Source form: Inj Sol-1mL Pk (Preservative-Free); strength: 0.05mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $11.2500; ministry $11.2500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02413620 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89827

Interchangeable products

Baclofen Injection · DIN 02457059 · $11.2500 Lioresal Intrathecal · DIN 02131048 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413620

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Baclofen Intrathecal · DIN 02413639 Manufacturer: Sterimax Inc.; listing date 2015-08-26 Health Canada: Marketed since 2018-01-11 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 10 MG/20ML · company Sterimax inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02413639). DIN 02413639: Baclofen Intrathecal Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 122000022; group id 240; item number 0429; lccId None; manufacturer id STE Source form: Inj Sol-20mL Pk (Preservative-Free); strength: 0.5mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $177.2500; ministry $177.2500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02413639 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89828

Interchangeable products

Baclofen Injection · DIN 02457067 · $177.2500 Baclofen Intrathecal · DIN 02485508 · $177.2500 Lioresal Intrathecal · DIN 02131056 · not recorded

Shortage status: resolved shortage (ended 2017-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413639

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Baclofen Intrathecal · DIN 02485508 Manufacturer: Avir Pharma Inc.; listing date 2021-09-30 Health Canada: Marketed since 2021-07-20 · brand BACLOFEN INTRATHECAL · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 0.5 MG/ML · company Avir pharma inc. · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02485508). DIN 02485508: Baclofen Intrathecal Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 122000022; group id 240; item number 0429; lccId None; manufacturer id AVP Source form: Inj Sol-20mL Pk (Preservative-Free); strength: 0.5mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $177.2500; ministry $177.2500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485508 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97574

Interchangeable products

Baclofen Injection · DIN 02457067 · $177.2500 Baclofen Intrathecal · DIN 02413639 · $177.2500 Lioresal Intrathecal · DIN 02131056 · not recorded

Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485508

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Baclofen Injection · DIN 02457075 Manufacturer: Teligent OU; listing date 2019-02-28 Health Canada: Marketed since 2023-05-26 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 2 MG/ML · company Hikma canada limited · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02457075). DIN 02457075: Baclofen Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id TEL Source form: Inj Sol (Preservative-Free); strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $35.4500; ministry $35.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457075 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94416

Interchangeable products

Baclofen Injection USP · DIN 02553341 · $35.4500 Baclofen Intrathecal · DIN 02413647 · $35.4500 Baclofen Intrathecal · DIN 02485516 · $35.4500 Lioresal Intrathecal · DIN 02131064 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457075

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Baclofen Injection USP · DIN 02553341 Manufacturer: Jamp Pharma Corporation; listing date 2025-07-31 Health Canada: Marketed since 2025-11-10 · brand BACLOFEN INJECTION USP · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 2 MG/ML · company Jamp pharma corporation · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02553341). DIN 02553341: Baclofen Injection USP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id JPC Source form: Inj Sol (Preservative-Free); strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $35.4500; ministry $35.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553341 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104229

Interchangeable products

Baclofen Injection · DIN 02457075 · $35.4500 Baclofen Intrathecal · DIN 02413647 · $35.4500 Baclofen Intrathecal · DIN 02485516 · $35.4500 Lioresal Intrathecal · DIN 02131064 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02553341

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Baclofen Intrathecal · DIN 02413647 Manufacturer: Sterimax Inc.; listing date 2015-08-26 Health Canada: Marketed since 2018-01-11 · brand BACLOFEN INJECTION · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 10 MG/5ML · company Sterimax inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02413647). DIN 02413647: Baclofen Intrathecal Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id STE Source form: Inj Sol (Preservative-Free); strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $35.4500; ministry $35.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02413647 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89829

Interchangeable products

Baclofen Injection · DIN 02457075 · $35.4500 Baclofen Injection USP · DIN 02553341 · $35.4500 Baclofen Intrathecal · DIN 02485516 · $35.4500 Lioresal Intrathecal · DIN 02131064 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413647

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Baclofen Intrathecal · DIN 02485516 Manufacturer: Avir Pharma Inc.; listing date 2021-09-30 Health Canada: Marketed since 2021-07-20 · brand BACLOFEN INTRATHECAL · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 2 MG/ML · company Avir pharma inc. · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02485516). DIN 02485516: Baclofen Intrathecal Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id AVP Source form: Inj Sol (Preservative-Free); strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $35.4500; ministry $35.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485516 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97575

Interchangeable products

Baclofen Injection · DIN 02457075 · $35.4500 Baclofen Injection USP · DIN 02553341 · $35.4500 Baclofen Intrathecal · DIN 02413647 · $35.4500 Lioresal Intrathecal · DIN 02131064 · not recorded

Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485516

Shortage record checked 2026-09-13T08:10:21.292534+00:00